Literature DB >> 28229811

Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria.

Serge Perrot1, Mariana Peixoto2, Philippe Dieudé3, Eric Hachulla4, Jerome Avouac2, Sebastien Ottaviani3, Yannick Allanore2.   

Abstract

OBJECTIVES: Fibromyalgia (FM) may occur with rheumatoid arthritis (RA) and systemic sclerosis (SSc), and debate remains about its diagnosis. We aimed to use three FM tools (a screening tool (FiRST), diagnostic criteria (ACR 1990 and revised 2010), to compare FM prevalence between RA and SSc patients, to describe the phenotypes of patients with comorbid FM, and to analyze links between FM and secondary Sjögren's syndrome (SS).
METHODS: Consecutive adult patients with confirmed RA or SSc from four university hospitals were tested with the three FM tools.
RESULTS: FiRST detected FM in 22.6% of the 172 RA patients, with confirmation in 22.1% (ACR1990) and 19.1% (ACR2010). ACR1990FM+ RA patients had more diffuse pain, whereas ACR2010FM+ RA patients had higher BMI and pain intensity, more diffuse pain, active disease, disability, and associated SS. FiRST detected FM in 27.8% of the 122 SSc patients, with confirmation in 30.3% (ACR1990) and 23.7% (ACR2010). ACR1990FM+ SSc patients had greater disability and pain intensity, and more diffuse pain, whereas ACR2010FM+ SSc patients had higher BMI, pain intensity, more disability and diffuse pain, and associated SS. Correlations between FM diagnostic and screening tool results were modest in both conditions. Secondary SS was associated with comorbid FM.
CONCLUSIONS: The prevalence of FM is high in SSc and RA, whatever the FM diagnostic tool used. Secondary SS is associated with FM in both RA and SSc. The revised ACR 2010 FM criteria and FiRST screening tool reveal specific phenotypes potentially useful for improving disease management.

Entities:  

Mesh:

Year:  2017        PMID: 28229811

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis.

Authors:  Daniela Santos-Faria; Maxime Dougados; Laure Gossec; Serge Perrot; Anna Moltó
Journal:  Rheumatol Int       Date:  2018-11-09       Impact factor: 2.631

Review 2.  Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Authors:  Eleni Pagkopoulou; Alexandra Arvanitaki; Dimitrios Daoussis; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2019-07-12       Impact factor: 2.631

3.  Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias.

Authors:  Frederick Wolfe; Brian Walitt; Serge Perrot; Johannes J Rasker; Winfried Häuser
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

4.  Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease.

Authors:  Waleed Hafiz; Rawad Nori; Ariana Bregasi; Babak Noamani; Dennisse Bonilla; Larissa Lisnevskaia; Earl Silverman; Arthur A M Bookman; Sindhu R Johnson; Carolina Landolt-Marticorena; Joan Wither
Journal:  Arthritis Res Ther       Date:  2019-11-04       Impact factor: 5.156

5.  Research Recommendations Following the Discovery of Pain Sensitizing IgG Autoantibodies in Fibromyalgia Syndrome.

Authors:  Andreas Goebel; David Andersson; Chris Barker; Neil Basu; Craig Bullock; Stuart Bevan; Rachael J M Bashford-Rogers; Ernest Choy; David Clauw; Debra Dulake; Richard Dulake; Herta Flor; Marcia Glanvill; Zsuzsanna Helyes; Sarosh Irani; Eva Kosek; Jennifer Laird; Gary MacFarlane; Hayley McCullough; Andrew Marshall; Robert Moots; Serge Perrot; Nick Shenker; Emanuele Sher; Claudia Sommer; Camilla I Svensson; Amanda Williams; Geoff Wood; Emma R Dorris
Journal:  Pain Med       Date:  2022-05-30       Impact factor: 3.637

6.  A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.

Authors:  Jeffrey R Curtis; Christopher Herrem; 'Matladi N Ndlovu; Cathy O'Brien; Yusuf Yazici
Journal:  Arthritis Res Ther       Date:  2017-09-29       Impact factor: 5.156

Review 7.  Comorbidity management in spondyloarthritis.

Authors:  Clementina López-Medina; Anna Molto
Journal:  RMD Open       Date:  2020-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.